CTRI/2020/08/027287进行中（未招募）4 期
A prospective, multicenter, Phase-IV clinical trial to assess safety of Durvalumab in Indian adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC)
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Provision of signed, written and dated informed consent prior to any study specific Procedures
- •2.Male or female aged 18 years or older
- •3.As per local prescribing information and in view of positive benefit-risk assessment, patient prescribed Durvalumab treatment as per independent clinical judgment of treating physician for either a. treatment for locally advanced, unresectable non-small cell lung carcinoma whose disease has not progressed following platinum-based chemoradiation therapy b treatment for locally advanced or metastatic urothelial carcinoma whose disease has progressed during or after platinum-based chemotherapy.
排除标准
- •1 Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study
- •2.Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.
- •3.Prior exposure to any anti-PD-1 or anti-PD-L1 antibody including durvalumab.
- •4.For NSCLC cohort only:
- •a.Mixed small cell and non-small cell lung cancer histology
- •b.Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy.
- •c.Patients with =Grade 2 pneumonitis from prior chemoradiation therapy
- •5.Active or prior documented autoimmune disease within the past 2 years, inflammatory bowel disease (eg, Crohn’s disease, ulcerative colitis), primary immunodeficiency, organ transplant that requires therapeutic immunosuppression, hypersensitivity to study drug or any excipient, leptomeningeal carcinomatosis, tuberculosis.
- •NOTE: Patients with vitiligo, Grave’s disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
- •6.Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control
- •7.Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of patient safety or study results.
研究者
相似试验
已完成
4 期
A prospective, multicentre study to see the safety of Osimertinib in Indian adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive nonsmall cell lung cancer.CTRI/2018/10/015941AstraZeneca Pharma India Limited60
已完成
4 期
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Ovarian Cancer and Metastatic Breast CancerCTRI/2020/03/024196AstraZeneca Pharma India Ltd200
已完成
4 期
A study to see the safety and efficacy of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukaemia and relapsed and refractory mantle cell lymphomaCTRI/2021/04/033224AstraZeneca Pharma India Ltd103
已完成
4 期
Phase -IV study to check the safety of fixed dose combination of dapagliflozin and saxagliptin in Indian Type 2 Diabetes Mellitus patientsCTRI/2021/02/031471AstraZeneca Pharma India Ltd196
已完成
4 期
A clinical study to assess the safety of BEs Typhoid vaccine when co-administered with licensed Measles-Rubella (MR) vaccineCTRI/2022/02/040285Biological E Limited1,252